Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03058289 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
A Phase 1 study, sponsored by Intensity Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 111
- Enrollment target
NCT03058289 is a Phase 1 study that has completed, run by Intensity Therapeutics. The registered enrollment target is 111 participants.
The verdict
NCT03058289, a Phase 1 study, has completed, sponsored by Intensity Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 111 participants
- Enrollment target
Study Summary
This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the skin (breast, squamous cell, head and neck) and tumors within the body such (pancreatic, colon, liver, lung, etc.). Sponsor also tested INT230-6 in combination with anti-PD-1 and anti-CTLA-4 antibodies.
Interventions
- DRUG INT230-6
- BIOLOGICAL anti-PD-1 antibody
- BIOLOGICAL anti-CTLA-4 antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2017-02-09 |
| Est. Completion | 2023-02-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03058289
The ClinicalTrials.gov registry entry for NCT03058289 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intensity Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which INT230-6 is the first listed.
NCT03058289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03058289 about?
NCT03058289 is a clinical study titled "A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6". This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the skin (breast, squamous cell, head and neck) and tumors within the body ...
What is the current status of trial NCT03058289?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 111 participants. The study started on 2017-02-09. Estimated completion is 2023-02-22.
What interventions are being tested in trial NCT03058289?
The interventions under investigation include: INT230-6 (DRUG), anti-PD-1 antibody (BIOLOGICAL), anti-CTLA-4 antibody (BIOLOGICAL).
Who is sponsoring clinical trial NCT03058289?
This trial is sponsored by Intensity Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.